Why did GPAT's expenses surge in Q2 2024?

The surge in GPAT's operating expenses in Q2 2024 cannot be directly attributed to the available data. However, we can infer potential reasons based on related information: 1. **Strategic Review and Asset Monetization**: GPAT is currently undergoing a strategic review process to enhance shareholder value, which includes exploring asset monetization and reducing operating expenses. This strategic move might involve restructuring or optimizing existing operations, which could temporarily increase expenses before achieving long-term cost savings. 2. **Business Highlights and Financial Results**: Quell, a subsidiary of GPAT, saw a 47% revenue increase due to growth in the fibromyalgia indication. This positive trend suggests effective market penetration and product acceptance, which could indicate that any increased expenses might be yielding desirable outcomes in terms of revenue growth. In conclusion, GPAT's operating expenses surge in Q2 2024 might be a strategic decision for optimizing asset value and enhancing shareholder returns in the long term, despite short-term financial strain.